MAOB and Alzheimer disease: The significant alleviation in Aβ burden, anti-inflammatory and antioxidative effects, and enhanced synaptic transmission activity were also observed in the hippocampus.530 Given the elevated activity of monoamine oxidase-B (MAO-B) observed in AD, dual inhibition of AChE and MAO-B holds promise for synergistic effects on cholinergic system recovery and Aβ plaque formation, along with potential benefits in alleviating oxidative stress injury.531 Ladostigil (46), an AChE/MAO-B inhibitor developed through a pharmacophore fusion strategy,532 has completed a clinical phase II trial (NCT01429623).